Relay Therapeutics, Inc.
small molecule precision medicines (computational structure-based drug discovery)
RLAY · Nasdaq · United States
Share price · RLAY
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when RLAY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 9 Nov 2026+9.6%
Nothing announced by RLAY that day or the session before.
- 6 Nov 2026+9.4%
- Day beforeEarnings date (period ending 2026-09-30)
- 30 Oct 2026-5.8%
Nothing announced by RLAY that day or the session before.
- 20 Oct 2026+8.0%
Nothing announced by RLAY that day or the session before.
- 21 Sep 2026-3.5%
Nothing announced by RLAY that day or the session before.
- 2 Jun 2026+10.1%
Nothing announced by RLAY that day or the session before.
- 28 Apr 2026-12.8%
- 7 Apr 2026+8.3%
Nothing announced by RLAY that day or the session before.
- 2 Apr 2026+16.4%
- 1 Apr 2026+8.2%
Nothing announced by RLAY that day or the session before.
Share of unusual movement by asset
For each asset, the share of RLAY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
lirafugratinib(Lyrfigtu) | Approved | FGFR2Small molecule | Biliary Tract Cancer Cholangiocarcinoma |
| Phase 3 | PI3K-alpha (mutant-selective)Small molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
September 2027 (1)
What to watch
2028 (1)
April 2028 (1)
What to watch
2031 (1)
July 2031 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $77M | $125M | $82M-$64M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0.3M | $76M | $123M | $84M-$54M operating cash flow | report ↗ |
| 2026-Q1 | $3.0M | $71M | $206M | $73M-$51M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $68M | $94M | $74M-$62M operating cash flow | report ↗ |
| 2025-Q2 | $0.7M | $64M | $116M | $70M-$55M operating cash flow | report ↗ |
| 2025-Q1 | $7.7M | $74M | $96M | $77M-$73M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $77M | $154M | $88M-$75M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $92M | $137M | $92M-$66M operating cash flow | report ↗ |
| 2024-Q1 | $10M | $82M | $156M | $81M-$50M operating cash flow | report ↗ |
| 2023-Q3 | $25M | $81M | $154M | $66M-$75M operating cash flow | report ↗ |
| 2023-Q2 | $0.1M | $88M | $149M | $99M-$69M operating cash flow | report ↗ |
| 2023-Q1 | $0.2M | $83M | $164M | $94M-$67M operating cash flow | report ↗ |
| 2022-Q3 | $0.3M | $67M | $357M | $84M-$66M operating cash flow | report ↗ |
| 2022-Q2 | $0.4M | $61M | $110M | $77M-$57M operating cash flow | report ↗ |
| 2022-Q1 | $0.4M | $52M | $122M | $62M-$49M operating cash flow | report ↗ |
| 2021-Q3 | $0.7M | $45M | $231M | $61M-$53M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $15M | $261M | $85M | $69M-$235M operating cash flow | report ↗ |
Relay Therapeutics reported full-year 2025 revenue of $15.36M, up 53.4% YoY, while R&D expenses declined 18.1% YoY to $261.38M. The company ended the period with cash, cash equivalents, and investments of approximately $554.5M and reported a net loss of $276.5M, or $1.61 per share.
The company guided that its current cash position is expected to fund operations into 2029. Anticipated 2026 milestones include initial Phase 1 data for zovegalisib in PIK3CA-driven vascular anomalies in the first half of 2026, breast cancer triplet data and frontline Phase 3 plans during 2026, and presentation of initial Phase 1/2 data for zovegalisib plus fulvestrant at the Phase 3 dose at ESMO TAT on March 16, 2026. Zovegalisib recently received Breakthrough Therapy designation from the FDA.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $10M | $319M | $126M | $84M-$249M operating cash flow | report ↗ |
| 2023-FY | $26M | $330M | $146M | $85M-$300M operating cash flow | report ↗ |
| 2022-FY | $1.4M | $246M | $154M | $73M-$229M operating cash flow | report ↗ |
| 2021-FY | $3.0M | $173M | $283M | $91M-$74M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 39 sales ($129.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-28 | Catinazzo Thomas · Chief Financial Officer | Open-market sale | 1,469 | $18.62 | $27K | Form 4 |
| 2026-10-28 | Bergstrom Donald A · President, R&D | Open-market sale | 2,252 | $18.62 | $42K | Form 4 |
| 2026-10-28 | Rahmer Peter · See remarks | Open-market sale | 753 | $18.62 | $14K | Form 4 |
| 2026-10-07 | Patel Sanjiv · director, President and CEO | Open-market sale | 48,199 | $18.10 | $872K | Form 4 |
| 2026-10-06 | Catinazzo Thomas · Chief Financial Officer | Open-market sale | 17,511 | $18.58 | $325K | Form 4 |
| 2026-10-06 | Catinazzo Thomas · Chief Financial Officer | Open-market sale | 206 | $19.26 | $4K | Form 4 |
| 2026-09-08 | Patel Sanjiv · director, President and CEO | Open-market sale | 48,199 | $18.94 | $913K | Form 4 |
| 2026-09-08 | Catinazzo Thomas · Chief Financial Officer | Open-market sale | 17,717 | $18.94 | $336K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 241 reporting institutions held 184.6M shares ($1.8B, 83.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | SB INVESTMENT ADVISERS (UK) LTD | 27,904,963 | $277.7M |
| 2 | Commodore Capital LP | 17,000,000 | $169.2M |
| 3 | Casdin Capital, LLC | 14,418,574 | $143.5M |
| 4 | BlackRock, Inc. | 12,975,299 | $129.1M |
| 5 | PERCEPTIVE ADVISORS LLC | 9,751,141 | $97.0M |
| 6 | Bellevue Group AG | 7,795,242 | $77.6M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 7,387,465 | $73.5M |
| 8 | STATE STREET CORP | 6,233,545 | $62.0M |
| 9 | Nextech Invest, Ltd. | 5,526,506 | $55.0M |
| 10 | TCG Crossover Management, LLC | 4,273,356 | $42.5M |
| 11 | FMR LLC | 3,695,431 | $36.8M |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 3,510,636 | $34.9M |
| 13 | Balyasny Asset Management L.P. | 3,039,179 | $30.2M |
| 14 | Spruce Street Capital LP | 2,984,125 | $29.7M |
| 15 | DIMENSIONAL FUND ADVISORS LP | 2,940,536 | $29.2M |